- Shear-Wave Elastography of the Breast: Added Value of a Quality Map in Diagnosis and Prediction of the Biological Characteristics of Breast Cancer
-
Zheng X, Huang Y, Liu Y, Wang Y, Mao R, Li F, Cao L, Zhou J
- KMID: 2471634
- Korean J Radiol.
- 2020 Feb;21(2):172-180.
- doi: 10.3348/kjr.2019.0453
OBJECTIVE: To determine the added value of a shear-wave elastography (SWE) quality map (QM) in the diagnosis of breast lesions and in predicting the biological characteristics of invasive breast cancer. MATERIALS... -
- CITED
-
- Close
- SHARE
-
- Close
- Expression of Histo-blood Group Antigens in Tumor and Adjacent Normal Breast Tissues as Prognostic Markers of Breast Carcinoma
-
Zouine S, Marnissi F, Otmani N, Bennani Othmani M, Zaid N, Kojok K, Zaid Y, Tahiri Jouti N, Habti N
- KMID: 2470883
- J Breast Cancer.
- 2020 Feb;23(1):69-79.
- doi: 10.4048/jbc.2020.23.e13
PURPOSE: Aberrant glycosylation of the histo-blood group antigens (including the angina bullosa haemorrhagica [ABH]) is often observed during malignant transformation in most types of carcinomas. Data concerning their ethnic distributions... -
- CITED
-
- Close
- SHARE
-
- Close
- Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma
-
Kim T, Cha YJ, Chang YS
- KMID: 2466620
- Tuberc Respir Dis.
- 2020 Jan;83(1):51-60.
- doi: 10.4046/trd.2019.0026
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression is tested by immunohistochemistry (IHC)—22C3, SP263, and SP142. The aim of this study is to evaluate the correlation among the three methods of PD-L1... -
- CITED
-
- Close
- SHARE
-
- Close
- Current Status of Immunotherapy for Lung Cancer and Future Perspectives
-
Kim HC, Choi CM
- KMID: 2466616
- Tuberc Respir Dis.
- 2020 Jan;83(1):14-19.
- doi: 10.4046/trd.2019.0039
Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatic resection for isolated stomach cancer liver metastases: A single-center experience
-
Kim H, Seo HI
- KMID: 2470668
- Korean J Clin Oncol.
- 2019 Dec;15(2):68-71.
- doi: 10.14216/kjco.19013
PURPOSE: The objective of this study was to investigate the outcomes of selected patients with stomach cancer liver metastasis (SCLM) without extrahepatic metastases after hepatic resection. METHODS: Patients whose imaging results... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Value of the Standardized Uptake Value of 18F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Assessing Axillary Lymph Node Metastasis in Different Subtypes of Breast Cancer
-
Kim N, Choi J, Ko EB, Kim SH, Jun J, Kim HA, Noh WC, Seong MK
- KMID: 2470605
- J Breast Dis.
- 2019 Dec;7(2):65-72.
- doi: 10.14449/jbd.2019.7.2.65
PURPOSE: This study aimed to examine the association between the maximum standardized uptake value (SUVmax) of different molecular subtypes of primary breast cancer with axillary lymph node (ALN) metastasis. METHODS: The... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinicopathological Significance of SMAD4 Expression in Breast Cancer
-
Woo JS, Chung MS, Paik SS
- KMID: 2470603
- J Breast Dis.
- 2019 Dec;7(2):52-58.
- doi: 10.14449/jbd.2019.7.2.52
PURPOSE: SMAD4 is a member of the SMAD family and acts as a central mediator of transforming growth factor beta signaling. Little is known about SMAD4 expression and its prognostic... -
- CITED
-
- Close
- SHARE
-
- Close
- Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
-
Jeong I, Song J, Bae SY, Lee SK
- KMID: 2468811
- J Cancer Prev.
- 2019 Dec;24(4):217-223.
- doi: 10.15430/JCP.2019.24.4.217
BACKGROUND: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is a limited factor in the treatment of non-small-cell lung cancer (NSCLC) patients. Therefore, ongoing studies... -
- CITED
-
- Close
- SHARE
-
- Close
- An Updated Nomogram for Predicting Invasiveness in Preoperative Ductal Carcinoma In Situ of the Breast
-
Kim S, Kim J, Park HS, Kim HY, Lee K, Lee J, Lee H, Kim JY, Kim SI, Cho YU, Park BW
- KMID: 2460219
- Yonsei Med J.
- 2019 Nov;60(11):1028-1035.
- doi: 10.3349/ymj.2019.60.11.1028
PURPOSE: To validate and update a nomogram for predicting ductal carcinoma in situ (DCIS) upstaging in preoperative biopsy. MATERIALS AND METHODS: Medical records of 444 preoperative DCIS patients were evaluated and... -
- CITED
-
- Close
- SHARE
-
- Close
- Discordance of Epidermal Growth Factor Receptor Mutation between Brain Metastasis and Primary Non-Small Cell Lung Cancer
-
Kim KM, Lee SH, Kim SM, Kim NY, Gwak HS, Shin SH, Kwon JW, Yoo H
- KMID: 2461187
- Brain Tumor Res Treat.
- 2019 Oct;7(2):137-140.
- doi: 10.14791/btrt.2019.7.e44
BACKGROUND: The aim of this study was to compare epidermal growth factor receptor (EGFR) mutations between non-small cell lung cancer (NSCLC) and corresponding brain metastases (BMs) in Korea society. METHODS: From... -
- CITED
-
- Close
- SHARE
-
- Close
- Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014
-
Choi CM, Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, Ahn JS, Kim SJ, Kim Y, Choi YD, Suh YG, Kim JE, Lee B, Won YJ, Kim YC
- KMID: 2460589
- Cancer Res Treat.
- 2019 Oct;51(4):1400-1410.
- doi: 10.4143/crt.2018.704
PURPOSE: The aim of this study was to investigate epidemiology, clinical characteristics and sex differences of patients with lung cancer using nationwide registry in Korea. MATERIALS AND METHODS: The Korean Association... -
- CITED
-
- Close
- SHARE
-
- Close
- Current Development and Research Trend of Chemotherapeutic Agents for Head and Neck Squamous Cell Carcinoma
-
Lee YS
- KMID: 2461000
- Korean J Otorhinolaryngol-Head Neck Surg.
- 2019 Sep;62(9):487-498.
- doi: 10.3342/kjorl-hns.2019.00479
After FDA approval of cetuximab at 2006, receptor tyrosine kinase, including an epidermal growth factor receptor, blocking agents have been evaluated for head and neck squamous cell carcinoma (HNSCC). Agents... -
- CITED
-
- Close
- SHARE
-
- Close
- Local ablative radiotherapy for oligometastatic non-small cell lung cancer
-
Suh YG, Cho J
- KMID: 2460739
- Radiat Oncol J.
- 2019 Sep;37(3):149-155.
- doi: 10.3857/roj.2019.00514
In metastatic non-small cell lung cancer (NSCLC), the role of radiotherapy (RT) has been limited to palliation to alleviate the symptoms. However, with the development of advanced RT techniques, recent... -
- CITED
-
- Close
- SHARE
-
- Close
- Human Epidermal Growth Factor Receptor 2-Subtype Invasive Ductal Carcinoma Recurring as Basal-Human Epidermal Growth Factor Receptor 2-Subtype Squamous Cell Carcinoma
-
An J, Yoo Y, Kim HG, Woo J, Lee KE, Kwon H, Lim W, Sung SH, Paik NS, Moon BI
- KMID: 2458868
- J Breast Cancer.
- 2019 Sep;22(3):484-490.
- doi: 10.4048/jbc.2019.22.e31
Squamous cell carcinoma of the breast and its subtype, basal-human epidermal growth factor receptor 2 (HER2) phenotype, are very rare. Herein, we report a patient who developed recurrence of squamous... -
- CITED
-
- Close
- SHARE
-
- Close
- Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer
-
Bae SJ, Ahn SG, Yoon CI, Yang BS, Lee HW, Son EJ, Jeong J
- KMID: 2458865
- J Breast Cancer.
- 2019 Sep;22(3):453-463.
- doi: 10.4048/jbc.2019.22.e36
PURPOSE: We evaluated the clinical value of breast magnetic resonance imaging (MRI) in patients who underwent breast-conserving surgery (BCS). The degree of correlation between pathology size and MRI or ultrasonography... -
- CITED
-
- Close
- SHARE
-
- Close
- Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value
-
Woo JW, Chung YR, Ahn S, Kang E, Kim EK, Kim SH, Kim JH, Kim IA, Park SY
- KMID: 2458864
- J Breast Cancer.
- 2019 Sep;22(3):439-452.
- doi: 10.4048/jbc.2019.22.e38
PURPOSE: There is cumulative evidence that changes in biomarker status occur frequently during the metastatic progression of breast cancer and affect treatment response. The purpose of this study was to... -
- CITED
-
- Close
- SHARE
-
- Close
- Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtypeâ» Breast Cancer
-
Kim HS, Yoo TK, Park WC, Chae BJ
- KMID: 2458862
- J Breast Cancer.
- 2019 Sep;22(3):412-424.
- doi: 10.4048/jbc.2019.22.e35
PURPOSE: Neoadjuvant chemotherapy (NAC) is less effective for luminal breast cancer because luminal breast cancer has a lower rate of pathological complete response (pCR) after NAC than human epidermal growth... -
- CITED
-
- Close
- SHARE
-
- Close
- Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
-
Nakhjavani M, Hardingham JE, Palethorpe HM, Price TJ, Townsend A
- KMID: 2458857
- J Breast Cancer.
- 2019 Sep;22(3):341-361.
- doi: 10.4048/jbc.2019.22.e39
Breast cancer (BC) is still the most common cancer among women worldwide. Amongst the subtypes of BC, triple negative breast cancer (TNBC) is characterized by deficient expression of estrogen, progesterone,... -
- CITED
-
- Close
- SHARE
-
- Close
- Overexpression of HER2/HER3 and clinical feature of ovarian cancer
-
Chung YW, Kim S, Hong JH, Lee JK, Lee NW, Lee YS, Song JY
- KMID: 2457153
- J Gynecol Oncol.
- 2019 Sep;30(5):e75.
- doi: 10.3802/jgo.2019.30.e75
OBJECTIVES: Human epidermal growth factor receptor-2 (HER2) and 3 (HER3) belong to the epidermal growth factor receptor (EGFR) family of transmembrane receptor tyrosine kinases. In this study, we assessed HER2/HER3... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
-
Heo MH, Kim HK, Lee H, Kim JY, Ahn JS, Im YH, Park YH
- KMID: 2457033
- Korean J Intern Med.
- 2019 Sep;34(5):1100-1106.
- doi: 10.3904/kjim.2017.226
BACKGROUND/AIMS: We conducted a retrospective analysis of the clinical activity of fulvestrant in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) previously... -
- CITED
-
- Close
- SHARE
-
- Close
